News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
TILT Biotherapeutics, a Finnish company developing cancer immunotherapies, reported the final close of its €22m (US$23.8m) round, which was led by Finland’s Lifeline Ventures, an early-stage venture capital firm.
Releasing the first global Phase 3 data for crovalimab, Roche highlights the potential for 'robust disease control with less frequent treatment intervals'.
Around 25% of US venture capital biopharma investments flowed to Massachusetts in 2022: cementing the state’s position as a leader in the industry. But how will economic uncertainty affect the hub’s fortunes moving forward?
US contract development and manufacturing organization, Catalent, reported results today for the second quarter of fiscal 2023, which ended December 31, 2022.